169 related articles for article (PubMed ID: 6754067)
1. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF.
Bezwoda WR; Derman D; De Moor NG; Lange M; Levin J
Cancer; 1982 Dec; 50(12):2747-50. PubMed ID: 6754067
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer.
Glick JH; Creech RH; Torri S; Holroyde C; Brodovsky H; Catalano RB; Varano M
Breast Cancer Res Treat; 1981; 1(1):59-68. PubMed ID: 6756508
[TBL] [Abstract][Full Text] [Related]
3. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
4. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
Colleoni M; Li S; Gelber RD; Coates AS; Castiglione-Gertsch M; Price KN; Lindtner J; Rudenstam CM; Crivellari D; Collins J; Pagani O; Simoncini E; Thürlimann B; Murray E; Forbes J; Erzen D; Holmberg S; Veronesi A; Goldhirsch A
Ann Oncol; 2005 May; 16(5):716-25. PubMed ID: 15817593
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
Hartman AR; Fleming GF; Dillon JJ
Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
[TBL] [Abstract][Full Text] [Related]
7. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
8. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
Clavel B; Cappelaere JP; Guerin J; Klein T; Pommatau E; Berlie J
Sem Hop; 1982 Sep; 58(34):1919-23. PubMed ID: 6293073
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
[TBL] [Abstract][Full Text] [Related]
10. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
Glick JH; Creech RH; Torri S; Holroyde C; Brodovsky H; Catalano RB; Varano M
Cancer; 1980 Feb; 45(4):735-41. PubMed ID: 6986969
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
[TBL] [Abstract][Full Text] [Related]
13. CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
Mouridsen HT; Palshof T; Engelsman E; Sylvester R
Eur J Cancer (1965); 1980; Suppl 1():119-23. PubMed ID: 7032921
[No Abstract] [Full Text] [Related]
14. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
[TBL] [Abstract][Full Text] [Related]
17. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen.
Mouridsen HT; Rose C; Engelsmann E; Sylvester R; Rotmensz N
J Steroid Biochem; 1985 Dec; 23(6B):1141-6. PubMed ID: 3912619
[TBL] [Abstract][Full Text] [Related]
18. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women.
Taylor SG; Gelman RS; Falkson G; Cummings FJ
Ann Intern Med; 1986 Apr; 104(4):455-61. PubMed ID: 3513684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]